OncXerna Therapeutics Announces New Biomarker Data from Retrospective Analysis of Results from Phase 1b Ovarian Cancer Trial of Navicixizumab Plus Paclitaxel at the ESGO 2021 Congress

NEXT STORY
Turning Point Therapeutics Presents Early Clinical Data for Repotrectinib From Care Study in Pediatric and Young Adult Patients at SIOP 2021 Virtual Congress
PREV STORY
Advanced Radiation Therapy, LLC and Apollo Healthcare Announce Strategic Partnership
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Filgrastim Biosimilars Global Market Report 2021: COVID-19 Growth And Change To 2030

author_avatar
NASDAQ Market News

Novartis advances head-to-head superiority trials of Cosentyx® versus Humira®* and proposed biosimilar adalimumab**

SURPASS is the first head-to-head superiority trial versus proposed biosimilar adalimumab** in ankylosing spondylitis (AS)[1] EXCEED ...

author_avatar
NASDAQ Market News

Helix BioPharma Corp. Closes $6.0 Million Private Placement

author_avatar
NASDAQ Market News